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Abstract 
Chromosome 20 anomalies are well-known in 
hematological malignancies, being del(20q) and 
dicentric chromosome 20 the most frequent. In 
contrast, monosomy 20 that occurs in a variety of 
hematological neoplasms is less well characterized. 
Keywords 
Numerical chromosome anomalies, chromosome 
20, del(20q), gene repression. 
Clinics and pathology 
Disease 
Chronic and acute myeloid malignancies, 
myelodysplastic syndromes (MDS), acute 
lymphoblastic leukemia (ALL) and plasma cell 
neoplasms. 
Etiology 
Detected in both myeloid and lymphoid 
malignancies. 
Epidemiology 
Chronic myeloproliferative disorder in 20 
(9M/11F aged 29 to 80 years, median 65 years): 6 
myelofibrosis (MF), 6 polycythemia vera (PV), 3 
essential thrombocythemia (ET), 1 chronic 
myeloproliferative disorder (MPD), 1 MDS/MPD 
and there were 3 patients with chronic 
myelomonocytic leukemia.  
Chronic myeloid leukemia (CML) was diagnosed in 
56 patients at different time points and disease 
stages (29M/27F aged 8 to 85 years, median 49 
years).  
Myelodysplastic syndromes: 149 patients aged 1 
to 84 years have been reported (99M/49F, 1 
unknown); most patients were diagnosed with 
refractory anemia with excess of blasts (RAEB) (68 
patients), followed by myelodysplastic syndrome, 
NOS (35 patients), refractory anemia (RA) (25 
patients), refractory cytopenia with multilineage 
dysplasia (12 patients) and refractory anemia with 
ringed sideroblasts (9 patients). Among them, 25 
patients developed MDS after chemotherapy and/or 
radiation therapy for previous tumors.  
Acute myeloid leukaemia  (AML): More than 400 
patients with various AML types have been 
reported: 165 acute myeloid leukemia, NOS, 17 
acute myeloblastic leukemia with minimal 
differentiation (AML-M0), 29 acute myeloblastic 
leukemia without maturation (AML-M1),   71 acute 
myeloblastic leukemia with maturation (AML-M2), 
5acute promyelocytic leukemia (AML- M3), 35 
acute myelomonocytic leukemia (AML-M4), 16 
acute monoblastic leukemia (AML-M5), 69 acute 
erythroleukemia (AML-M6) and 19 acute 
megakaryoblastic leukemia (AML-M7). The 
estimated frequency of monosomy 20 in patients 
with myeloid malignancies and abnormal 
karyotypes is about 11% (Raza et al., 2011).  
Lymphoid malignancies 
Acute lymphoblastic leukemia More than 450 
reported patients; however up to half of these 
patients had hyperdiploid/polyploid or hypodiploid 
karyotypes with unknown significance of -20. The 
estimated frequency of isolated monosomy 20 in 
cytogenetically abnormal childhood ALL is about 
3% (Betts et al., 1990).  
Bilineage or biphenotypic leukemia (BAL) was 
diagnosed in 9 patients (4M/5F aged 9 to 60 years, 
median 27 years).  
Other malignancies Chronic lymphocytic 
leukemia (CLL) in 44, T-prolymphocytic leukemia 
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in 12 and about 200 patients with plasma cell 
neoplasm. However, because monosomy 20 was 
detected in various disease diseases stages in these 
patients, it is unclear if its occurrence is related to 
clonal evolution or to previous therapies and is a 
sign of therapy-related hidden myelodysplastic 
syndrome. 
Prognosis 
The presence of isolated monosomy 20 may be 
associated with premalignant haematological 
conditions and an indolent clinical course in 
chronic myeloproliferative disorders with similar 
prognosis as in patients with del(20q).  
In AML, monosomy 20 occurs in both noncomplex 
and highly complex karyotypes, therefore the 
presence of primary anomalies and the number of 
additional anomalies may be a strong prognostic 
factor. In these patients, monosomy 20 frequently 
occurs as part of highly complex karyotypes with 
combination of chromosome 5 and 7 abnormalities, 
conferring unfavorable prognosis and poor response 
to chemotherapy. Isolated monosomy 20 in 
childhood ALL may indicate favorable prognosis 
(Betts et al., 1990; Silengo et al., 1992) while in 
complex karyotypes the prognosis may depend on 
the presence of additional anomalies. 
 
 
Figure 1.  Karyotype and partial karyotypes showing monosomy of chromosome 20. 
Figure 2. True monosomy can be confirmed with the use of fluorescence in situ hybridization techniques applying locus specific 
LSI D20S108 (A) or chromosome 20 painting probes (Abbott Molecular/Vysis, US) showing (B). 
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Cytogenetics  
Identification of 20 monosomy in complex 
karyotypes or its combination with marker 
chromosomes may be an indicator of unbalanced 
rearrangements, such as the dic(17;20) in myeloid 
malignancy or dic(9;20) in acute lymphoid 
leukaemia. Therefore, to confirm true monosomy 
20, accurate karyotyping and the use of 
fluorescence in situ hybridization techniques with 
locus specific or chromosome painting probes is 
recommended. Because apparent monosomy 20 in 
complex karyotypes can be frequently 
misclassification of unbalanced chromosome 20 
rearrangements, it is probably that true monosomy 
20 is less frequent than it is reported. 
Additional anomalies 
Chronic myeloproliferative disorders: most patients 
had simple karyotypes and only 5 of them had 
highly complex aberrations; sole anomaly in 2, 
found in association with del(20q) in 3, +8 in 4,  
del(5q)/-5 in 5, del(13q) in 2  and monosomy 7 in 2.  
CML: In 11 patients receiving tyrosine kinase 
inhibitor therapy or bone marrow transplant, 
monosomy 20 was detected in Philadelphia-
negative cells. Among them, it was a sole anomaly 
in 5 and in 4 it was found in association with 
monosomy 22.  Found as a sole additional anomaly 
tot(9;22) in 1 and with +der(22)t(9;22) in 21 
patients.  
MDS: Sole anomaly in 1, found in a sideline 
45,XY,-3/45,XY,-4/45,XY,-7/45,XY,-20 in 1; 
found with, del(20),+mar in 1 and in a sideline with 
del(20)(q11) in 1. The majority of remaining 
patients had complex and highly complex 
aberrations with monosomy 5/del(5q) and less 
frequently chromosome 7 abnormalities or their 
combination.   
AML: Sole anomaly in 6, in 4 of them found in a 
sideline. Rarely detected with well-known primary 
chromosome translocations; found in association 
with 4 t(9;22)(q34;q11) in 4, t(8;21)(q22;q22) in 2, 
inv(16)(p13q22)/t(16;16) in 2 and t(1;22)(p13;q13) 
in 3 AML-M7 patients. Mainly found as a part of 
complex and highly complex karyotypes and 
unstable clones with frequent chromosome 5 and/or 
7 abnormalities or both abnormalities together 
(about 2/3 of patients) and with commonly 
observed chromosomal abnormalities characteristic 
for myeloid malignancies such as +8 and 12p, 13q 
and 17p deletions and loss of a sex chromosome.   
ALL: Sole anomaly in 19 pediatric and 4 adult B-
ALL patients; about half of patients presented with 
hyperdiploid (about 200 patients), polyploid (10 
patients) or hypodiploid (about 50 patients) 
karyotypes. The remaining patients presented 
mainly with complex karyotypes, with relative low 
frequency of primary anomalies, being 
t(9;22)(q34;q11) the most frequent, that has been 
detected in 35 B-ALL patients. Among them, -20 
was detected as a sole additional anomaly to t(9;22) 
in 4 patients.  Other primary anomalies were less 
frequent, the t(1;19)(q23;p13) has been detected 
only in 5 and t(4;11) in 2 patients.  
BAL: Found as part of complex karyotypes in 
association with t(9;22)(q34;q11) in 2 and with -
5/del(5q) and/or -7/del(7q) in 4 out of 9 patients. 




Monosomy 20 is a non-random chromosome 
abnormality that has been reported in a variety of 
hematological neoplasms, including 
myelodysplastic syndromes, acute myeloid 
leukemia, Philadelphia chromosome-negative 
myeloproliferative neoplasms and acute 
lymhoblastic leukemia. Monosomy 20 results in 
haploinsufficiency of genes leading to a loss of 
expression, which may contribute to the 
development of malignancy. While the 
pathogenesis remains unknown, monosomy 20 is 
presumed to remove tumor suppressors at 20q12, 
the common deleted region of the well-known 20q 
deletion. Such candidate tumor suppressors may 
include L3MBTL1 and SGK2 and their repression 
may contribute to the development of malignancy 
by inducing replicative stress, DNA damage, and 
genomic instability. Isolated monosomy 20 could 
be an early event, although additional events need 
to accumulate for cancer development, while in 
complex karyotypes it is associated with unstable 
clones reflecting disease evolution. 
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